Connor Clark & Lunn Investment Management Ltd. Acquires 6,680 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 1.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 555,655 shares of the company’s stock after buying an additional 6,680 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Amneal Pharmaceuticals were worth $4,401,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Gladius Capital Management LP acquired a new position in Amneal Pharmaceuticals during the third quarter valued at approximately $37,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in Amneal Pharmaceuticals during the fourth quarter valued at approximately $81,000. Quest Partners LLC acquired a new position in Amneal Pharmaceuticals during the third quarter valued at approximately $84,000. Janney Montgomery Scott LLC acquired a new position in Amneal Pharmaceuticals during the fourth quarter valued at approximately $121,000. Finally, Quadrature Capital Ltd acquired a new position in Amneal Pharmaceuticals during the third quarter valued at approximately $169,000. 31.82% of the stock is owned by institutional investors.

Amneal Pharmaceuticals Stock Down 0.5 %

Amneal Pharmaceuticals stock opened at $8.75 on Monday. The stock has a market capitalization of $2.71 billion, a PE ratio of -12.87 and a beta of 1.05. Amneal Pharmaceuticals, Inc. has a twelve month low of $5.18 and a twelve month high of $9.48. The company has a 50 day moving average of $8.30 and a 200-day moving average of $8.36.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Friday, February 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.03). The business had revenue of $730.52 million during the quarter, compared to the consensus estimate of $708.21 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. During the same period in the prior year, the firm earned $0.14 EPS. Equities analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Insider Transactions at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director Gautam Patel sold 17,410 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $8.01, for a total transaction of $139,454.10. Following the sale, the director now directly owns 2,031,476 shares of the company’s stock, valued at approximately $16,272,122.76. This represents a 0.85 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 240,000 shares of company stock valued at $2,004,000 over the last 90 days. 26.56% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

AMRX has been the subject of a number of analyst reports. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $9.00 to $12.00 in a report on Monday, February 24th. StockNews.com cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th. Finally, Barclays upped their price target on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an “overweight” rating in a report on Monday, March 3rd. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Amneal Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $10.80.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.